Infectious Disease Companies Catch More Investors
This article was originally published in Start Up
Executive Summary
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
You may also be interested in...
Antibiotic Discovery Hurdles: Could Data Sharing, Research Hub Solve Problem?
With input from industry, Pew Charitable Trusts proposes formation of entity dedicated to basic research; first step is finding someone to fund the estimated $200m cost for five-year initiative.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
Anti-Infective R&D Ecosystem Getting Healthier, But Trials Remain
FDA and other government agencies have successfully nurtured a healthy ecosystem to rebuild the antibiotics pipeline, and a new crop of antibiotics has now reached the pivotal stage of clinical trials. But the sponsors are largely small companies: can they survive in the highly constrained commercial market for serious infections?